Minocycline in phenotypic models of Huntington's disease.
Minocycline has been shown to be neuroprotective in various models of neurodegenerative diseases. However, its potential in Huntington's disease (HD) models characterized by calpain-dependent degeneration and inflammation has not been investigated. Here, we have tested minocycline in phenotypic models of HD using 3-nitropropionic acid (3NP) intoxication and quinolinic acid (QA) injections. In the 3NP rat model, where the development of striatal lesions involves calpain, we found that minocycline was not protective, although it attenuated the development of inflammation induced after the onset of striatal degeneration. The lack of minocycline activity on calpain-dependent cell death was also confirmed in vitro using primary striatal cells. Conversely, we found that minocycline reduced lesions and inflammation induced by QA. In cultured cells, minocycline protected against mutated huntingtin and staurosporine, stimulations known to promote caspase-dependent cell death. Altogether, these data suggested that, in HD, minocycline may counteract the development of caspase-dependent neurodegeneration, inflammation, but not calpain-dependent neuronal death.
Bantubungi
Kadiombo
K
Laboratory of Neurophysiology, ULB-Erasme, Brussels, Belgium.
Jacquard
Carine
C
Greco
Anita
A
Pintor
Annita
A
Chtarto
Abdelwahed
A
Tai
Khalid
K
Galas
Marie-Christine
MC
Tenenbaum
Liliane
L
Déglon
Nicole
N
Popoli
Patrizia
P
Minghetti
Luisa
L
Brouillet
Emmanuel
E
Brotchi
Jacques
J
Levivier
Marc
M
Schiffmann
Serge N
SN
Blum
David
D
D000818:Animals; D002154:Calpain / Q000187:drug effects / Q000378:metabolism; D020169:Caspases / Q000187:drug effects / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D003342:Corpus Striatum / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004660:Encephalitis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D018698:Glutamic Acid / Q000378:metabolism; D000071058:Huntingtin Protein; D006816:Huntington Disease / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008911:Minocycline / Q000494:pharmacology* / Q000627:therapeutic use; D009410:Nerve Degeneration / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control*; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D009574:Nitro Compounds; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D010641:Phenotype; D011422:Propionates; D017378:Quinolinic Acid; D051381:Rats; D011917:Rats, Inbred Lew; D017208:Rats, Wistar; D019311:Staurosporine / Q000037:antagonists & inhibitors
C499524:Htt protein, rat; D000071058:Huntingtin Protein; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D009574:Nitro Compounds; D009687:Nuclear Proteins; D011422:Propionates; D018698:Glutamic Acid; D002154:Calpain; D020169:Caspases; D017378:Quinolinic Acid; D008911:Minocycline; D019311:Staurosporine; C015392:3-nitropropionic acid